Found 12 resultsAuthor [ Title] Type Year
Filters: Author is Anzala, O [Clear All Filters]
Acceptability and Feasibility of Repeated Mucosal Specimen Collection in Clinical Trial Participants in Kenya. PLoS One, 9, e110228. presented at the 10/2014. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25360819. (2014).
Assessment of Viral Inhibition Activity in Low Seroprevalent Adenovirus-35 Vectored HIV Vaccines +/- Adjuvanted Protein or Electroporated DNA. In HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P). presented at the 24/09/2014, Cape Town, SA. Retrieved from http://hivr4p.org/. (2014).
Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials. PLoS ONE, 3, e2043. presented at the 04/2008. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18446196. (2008).
Challenges of Use and Compliance With Effective Contraceptives Among Female Participants in Preventive HIV Vaccine Trials: The Kenyan Experience. In AIDS Vaccine 2007 Conference. presented at the 02/08/2007, Seattle, WA. Retrieved from http://www.vaccineenterprise.org/conference_archive/2007/index.html. (2007).
Clinical Safety and Immunogenicity of Two HIV Vaccines SeV-G(NP) and Ad35-GRIN in HIV-uninfected, Healthy Adult Volunteers. In HIVR4P (HIV Research for Prevention). presented at the 28/10/2014, Cape Town, South Africa. Retrieved from http://hivr4p.org/. (2014).
A Cross-Sectional Study in Eastern and Southern Africa to Characterize Laboratory Reference Intervals in Healthy Adults for HIV Prevention Trials. In AIDS Vaccine 2008 Conference. presented at the 13/10/2008, Cape Town, South Africa. Retrieved from http://www.vaccineenterprise.org/conference_archive/2008/index.html. (2008).
Development and validation of gamma interferon ELISPOT assay for HIV-1 vaccine trials in Kenya. presented at the 2004.. (2004).
Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate. In AIDS Vaccine 2005 International Conference. presented at the 06/09/2005, Montreal, Quebec, Canada.. (2005).
Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex Workers. PLoS One, 7, e33103. presented at the 04/2012. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22511916. (2012).
Safety and Immunogenicity Study of Multiclade HIV-1 Adeno-Viral Vector Vaccine Alone or as Boost Following a Multiclade HIV-1 DNA Vaccine in Africa. PLoS ONE, 5, e12873. presented at the 09/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20877623. (2010).
Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-Exposure Prophylaxis Among Men Who Have Sex With Men in Kenya. AIDS Behav, 19, 794-801. presented at the 05/2015. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/25432877. (2015).
Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of Human Immunodeficiency Virus-1 Vaccine Candidates. J Infect Dis, 201, 720-729. presented at the 03/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20132004. (2010).